Ivercure 40 mg Ivermectin Tablets

Ivermectin is an antiparasitic medicine used against certain susceptible parasites.

• Intestinal strongyloidiasis: FDA-approved oral ivermectin treatment for infection caused by Strongyloides stercoralis.

• Onchocerciasis: Used against Onchocerca volvulus, primarily reducing microfilariae rather than adult worms.

• Scabies: Off-label use in the United States. CDC guidance includes oral ivermectin as an option in selected cases, but it is not FDA-approved for scabies.

• Other parasitic infections: Use depends on the identified parasite, local guidance and professional assessment.

The appropriate indication should be confirmed before using a 40 mg tablet.

Ivermectin belongs to the avermectin class of antiparasitic medicines. It binds selectively to glutamate-gated chloride channels in susceptible parasite nerve and muscle cells. This increases chloride permeability, causing hyperpolarization, paralysis and ultimately death of susceptible parasites.

Its activity is parasite-specific. For example, ivermectin affects the microfilarial stage of Onchocerca volvulus but does not kill the adult worms. This is why patients treated for onchocerciasis may require clinical follow-up and, depending on the circumstances, further treatment.

The 40 mg tablet strength should not be used to determine an individual dose. U.S. ivermectin labeling uses weight-based dosing for its approved oral indications.

Treatment context	General label-based information
Strongyloidiasis	Approximately 200 mcg/kg as a single oral dose
Onchocerciasis	Approximately 150 mcg/kg as a single oral dose
Administration	U.S. labeling directs tablets to be taken with water on an empty stomach for these labeled indications
40 mg strength	Not a universal single dose; the prescribed amount depends on body weight and indication

These figures explain the weight-based nature of ivermectin treatment and are not an individualized dosing recommendation. Do not take one or more 40 mg tablets based solely on body weight calculations from a website.

Use Ivercure 40 mg only according to the instructions provided by the prescriber and the supplied product labeling.

• Confirm that Ivercure 40 mg is the exact strength prescribed.

• Swallow the tablet with water according to the prescribed directions.

• Do not add another ivermectin product to the treatment unless specifically instructed.

• Do not increase, repeat or change the dose without professional advice.

• Tell your healthcare professional about other medicines, especially warfarin, because increased INR has been reported with ivermectin.

• If treatment is for strongyloidiasis, follow-up testing may be needed to confirm clearance of infection.

Possible adverse effects of oral ivermectin include dizziness, drowsiness, nausea, diarrhea, abdominal discomfort, weakness, itching and rash. Some patients treated for onchocerciasis can experience inflammatory reactions as microfilariae die.

More serious reactions have been reported, including neurological effects, severe low blood pressure, seizures and serious skin reactions.

Storage and handling:

• Keep the tablets in their original packaging.

• Protect them from unsuitable heat and moisture.

• Keep out of reach of children.

• Follow the exact storage conditions printed on the supplied Ivercure 40 mg pack.

A product-specific storage temperature and pack configuration should not be published until the actual 40 mg manufacturer packaging is verified.

Do not use ivermectin if you have previously experienced hypersensitivity to ivermectin or an ingredient in the supplied formulation. Particular caution is required in people with significant exposure to Loa loa-endemic areas of West or Central Africa. Heavily infected individuals can experience serious neurological reactions following ivermectin treatment, so appropriate assessment and follow-up may be necessary.

Pregnancy requires medical advice because adequate controlled studies have not established ivermectin's safety during pregnancy. Ivermectin passes into human milk in low concentrations, so breastfeeding patients should discuss treatment with a healthcare professional. Safety and effectiveness have not been established in children weighing less than 15 kg (33 lb).

Large or inappropriate doses can cause serious toxicity. Reported overdose or neurotoxicity symptoms include severe dizziness, loss of coordination, confusion, seizures, altered consciousness and coma. Seek urgent medical attention for serious neurological symptoms, severe allergic reactions, difficulty walking, seizures or loss of consciousness.

Ivermectin is not FDA-authorized or approved for preventing or treating COVID-19.

This information is for general education and does not replace advice from a doctor, pharmacist or qualified healthcare professional.